Photo from Volastra Therapeutics/LinkedIn
Nov 3, 2023, 12:06
Volastra Therapeutics dosed the first patient in their Phase I/II clinical trial of VLS-1488
Volastra Therapeutics shared on their LinkedIn page:
”We’ve dosed the first patient in our Phase I/II clinical trial of VLS-1488, our internally discovered KIF18A inhibiting drug designed to treat patients with advanced cancers characterized by high levels of chromosomal instability.”
For more information click here.
Source: Volastra Therapeutics/LinkedIn